Original Study| Volume 15, ISSUE 6, P711-716, December 2017

Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study



      The present retrospective study analyzed the tolerance of orthotopic ileal neobladders to radiotherapy by reviewing the acute and late toxicity in patients who underwent postoperative radiotherapy after radical cystectomy/cystoprostatectomy.

      Materials and Methods

      A multi-institutional database was created for patients who had undergone radical cystectomy/cystoprostatectomy and neobladder reconstruction, followed by adjuvant radiotherapy (RT). The patient and tumor characteristics were recorded. The RT data were reviewed to determine the treatment technique used, the radiation dose received by the neobladder, and acute and late toxicity evaluated using the Common Terminology Criteria for Adverse Events, version 4.0, scale.


      A total of 25 patients were included, with a median age of 64 years. Of the 25 patients, 18 received a dose of 45 to 50.4 Gy. The most common reasons for postoperative radiotherapy were close or positive surgical margins and pT3-pT4 or N+ disease. Ten patients underwent intensity modulated RT. All but 1 patient completed the RT course. Of the patients who completed their RT schedule, none had grade ≥ 3 acute gastrointestinal toxicity. One patient who received concurrent chemotherapy developed grade 3 acute genitourinary toxicity. Three patients reported late grade 1 genitourinary toxicity (frequency of urination, mild leakage at night), with no reports of chronic gastrointestinal toxicity. None of the patients experienced neobladder perforation, leak, or fistula.


      The use of moderate doses of pelvic RT (range, 45-50.4 Gy) was well tolerated among the 25 patients who underwent RT after cystoprostatectomy with orthotopic neobladder creation. This finding supports the use of postoperative RT to moderate doses in this patient population when clinically indicated.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Christodouleas J.P.
        • Baumann B.C.
        • He J.
        • et al.
        Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710.
        Cancer. 2014; 120: 1272-1280
        • Reisinger S.A.
        • Mohiuddin M.
        • Mulholland S.G.
        Combined pre- and postoperative adjuvant radiation therapy for bladder cancer—a ten year experience.
        Int J Radiat Oncol Biol Phys. 1992; 24: 463-468
        • Zaghloul M.S.
        • Awwad H.K.
        • Omar S.
        • Soliman O.
        • el Attar I.
        Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control.
        Int J Radiat Oncol Biol Phys. 1992; 23: 511-517
        • Sargos P.
        • Baumann B.C.
        • Eapen L.J.
        • et al.
        Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?.
        Transl Androl Urol. 2016; 5: 702-710
        • Volkmer B.G.
        • Kuefer R.
        • Bartsch Jr., G.C.
        • Gust K.
        • Hautman R.E.
        Oncological followup after radical cystectomy for bladder cancer—is there any benefit?.
        J Urol. 2009; 181: 1587-1593
        • Cole C.J.
        • Pollack A.
        • Zagars G.K.
        • Dinney C.P.
        • Swanson D.A.
        • von Eschenbach A.C.
        Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.
        Int J Radiat Oncol Biol Phys. 1995; 32: 331-340
        • Pollack A.
        • Zagars G.K.
        • Cole C.J.
        • Dinney C.P.
        • Swanson D.A.
        • Grossman H.B.
        The relationship of local control to distant metastasis in muscle invasive bladder cancer.
        J Urol. 1995; 154: 2059-2064
        • Griffiths G.
        • Hall R.
        • Sylvester R.
        • Raghavan D.
        • Parmar M.K.
        • International Collaboration of Trialists
        • Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group)
        • European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group
        • Australian Bladder Cancer Study Group
        • National Cancer Institute of Canada Clinical Trials Group
        • Finnbladder
        • Norwegian Bladder Cancer Study Group
        • Club Urologico Espanol de Tratamiento Oncologico Group
        International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
        J Clin Oncol. 2011; 29: 2171-2177
        • Herr H.W.
        • Faulkner J.R.
        • Grossman H.B.
        • et al.
        Surgical factors influence bladder cancer outcomes: a cooperative group report.
        J Clin Oncol. 2004; 22: 2781-2789
        • El-Monim H.A.
        • El-Baradie M.M.
        • Younis A.
        • Ragab Y.
        • Labib A.
        • El-Attar I.
        A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer.
        Urol Oncol. 2013; 31: 359-365
        • Baumann B.C.
        • Noa K.
        • Wileyto E.P.
        • et al.
        Adjuvant radiation therapy for bladder cancer: a dosimetric comparison of techniques.
        Med Dosim. 2015; 40: 372-377
        • Baumann B.C.
        • Bosch W.R.
        • Bahl A.
        • et al.
        Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy.
        Int J Radiat Oncol Biol Phys. 2016; 96: 78-86